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Perivascular epithelioid cell tumors (PEComas) are rare soft-tissue tumors with an extremely heterogeneous clinical
behavior. They may arise in different organs and may behave indolently or sometimes metastasize with different
grades of biological aggressiveness. We report the case of a young woman with a primary inoperable PEComa of
the liver with malignant histological features. Since the mTOR pathway is often altered in PEComas and responses
have been reported with mTOR-inhibitors such as sirolimus or temsirolimus, we decided to start a neoadjuvant
treatment with sirolimus. The patient tolerated the treatment fairly well and after 8 months a favorable tumor
shrinkage was obtained. The patient then stopped sirolimus and 2 weeks later underwent partial liver resection,
with complete clinical recovery and normal liver function. The histological report confirmed a malignant PEComa
with vascular invasion and negative margins. Then 6 additional months of post-operative sirolimus treatment were
administered, followed by regular radiological follow-up. For patients with a large and histologically aggressive
PEComa, we think that neoadjuvant treatment with mTOR-inhibitor sirolimus may be considered to facilitate surgery
and allow early control of a potentially metastatic disease. For selected high-risk patients, the option of adjuvant
treatment may be discussed.
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Sarcomas are a heterogeneous, rare and complex group
of mesenchymal tumors, which can occur at any age and
in any part of the body. Rarity of the disease, heterogen-
eity of the site, grade and histology have been the major
determinants for the controversial results obtained in
clinical studies conducted so far in the management of
localized sarcomas [1].
The term perivascular epithelioid cell tumor (PEComa)
was first introduced by Zamboni et al. [2] to describe a
family of soft-tissue tumors characterized by melanocytic
and smooth muscle differentiation that may arise in dif-
ferent organs and are considered ubiquitous tumors.
The distinctive feature of PEComa is the perivascular ep-
ithelioid cell, a mesenchymal cell type frequently seen
adjacent to blood vessels. The so-called PEComa family
of tumors encompasses additional clinical entities such* Correspondence: umberto.basso@ioveneto.it
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reproduction in any medium, provided the oras angiomyolipoma, clear-cell sugar tumors of the lung,
lymphangioleiomyomatosis and unusual clear-cell tu-
mors of various organs [3]. Their biological behavior is
extremely heterogeneous, ranging from indolent and be-
nign forms to aggressive tumors with malignant trans-
formation and metastatic potential [4].
Due to the rarity and different sites of presentation,
the management of these tumors is still a matter of de-
bate in terms of the timing of surgery and the need for-
multimodal treatments. Here we report the case of a
young woman with a primitive PEComa of the liver who
underwent radical resection after neoadjuvant treatment
with sirolimus.Case presentation
A 31-year-old woman was first referred to our institu-
tion in January 2012 because vomiting and gastric reflux
had prompted a liver echography and a large hepatic
mass had been found. The patient was on an antidepres-
sant drug (ziprasidone) plus lansoprazole. She under-
went magnetic resonance imaging (MRI), which showedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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right lobe of the liver (Figure 1a). The biopsy showed
sheets of large epithelioid cells with abundant eosino-
philic cytoplasm and pleomorphic nuclei with prominent
nucleoli. Scattered multinuclear giant cells were present.
Mitotic activity was 4/50 high power fields (HPF) and
tumor necrosis was not observed (Figure 2). Immunohis-
tochemically, the tumor cells were strongly positive for
MelanA and microphthalmia transcription factor (MIFT),
and focally positive for HMB-45, desmin and smooth
muscle actin. Lymphovascular invasion was found in the
specimen. A diagnosis of epithelioid angiomyolipoma with
high-grade cellular atypia (epithelioid PEComa with malig-
nant potential) was therefore made, according to the cri-
teria proposed by Folpe and Kwiatkowski [4].
A total body computed tomography scan excluded the
presence of extra-hepatic disease and hematology, renal
and liver function tests were normal. Our gastrointes-
tinal Multidisciplinary Team discussed surgical options
but in consideration of the volume of the disease, very
close to hepatic veins, we decided to postpone surgery
and consider neoadjuvant treatment. PEComas are usu-
ally considered chemoresistant tumors, but published re-
ports of responses obtained with the mTOR-inhibitors
sirolimus and temsirolimus [5-9] provided the rationale
for the use of an agent of this class.
Two months later the patient started therapy with oral
sirolimus 2 mg per day continuatively, as compassionate
use authorized by the local Ethics Committee (Comitato
Etico of Istituto Oncologico Veneto (Padova, Italy)). In
the absence of toxicity at day 15, the dose was increased
to 3 mg per day. Her sirolimus plasma concentration
was regularly checked due to the risk that liver involve-
ment by the tumor and concomitant medications could
alter drug clearance. Trough values were in the range
from 12.6 to 20.1 μg/l, and therefore within therapeutic
range. Over the following weeks the patient experienced
gastrointestinal toxicity (diarrhea and gastric reflux,
grade 2 according to CTCAE), and so loperamide andFigure 1 Liver MRI scans. (a) At first diagnosis. (b) After 8 months of siroanalgesics were administered and there were a few short
treatment interruptions.
After 3 months, an MRI scan demonstrated a partial
response of the mass, with colliquation of its inner part
and a reduction of the internal vascularization. Thus, sir-
olimus was continued at the same dosage for another
5 months, when a new radiological assessment showed
further shrinkage of the tumor (Figure 1b).
After a multidisciplinary discussion confirmed resect-
ability of the mass, the patient stopped taking sirolimus
and 2 weeks later underwent resection of segments IVb, V
and VI. The surgical procedure was carried out free of
complications, with full recovery. All surgical margins
were negative at the final histological examination, which
confirmed malignant PEComa with vascular invasion.
The presence of intravascular tumor cells is a strongly
adverse prognostic factor for relapse of breast, colon and
other types of tumors, while its role in sarcomas is not
universally recognized [10]. However, in consideration of
the size and the malignant features of this tumor, as well
as fairly good tolerability of the drug, we decided to
administer 6 additional months of sirolimus as post-
operative treatment, still ongoing at the time of this writing.
Discussion
The definition of perivascular epithelioid cell neoplasia
or PEComa encompasses several types of tumors includ-
ing angiomyolipoma, clear-cell sugar tumors of the lung,
lymphangioleiomyomatosis and unusual clear-cell tu-
mors occurring in the kidney, pancreas, uterus or liver,
among others [3]. The majority of PEComas arise in
women, with a median age of 38 years [6]. They may
arise in different anatomical sites, even if they seem to
occur with more frequency in the retroperitoneum, ab-
dominal cavity and other viscera such as the gastrointes-
tinal tract, pelvis and liver [3,4].
PEComas are generally benign tumors, and usually do
not recur after surgical resection; however, a subgroup of
PEComas exhibits a combination of infiltrative growth,limus, showing a very good radiological response.
Figure 2 Tumor histology at first diagnosis.
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hypercellularity. These lesions have a malignant behavior,
with either local recurrence or metastatic spread, com-
monly in the lungs. Folpe and Kwiatkowski [4] reported an
association between malignant clinical behavior and a
tumor size greater than 5 cm, histological infiltrative pat-
tern, more than 1 mitosis/50 HPF and a high nuclear grade.
PEComas may be associated with the tuberous scler-
osis complex (TSC), an autosomal dominant neurocuta-
neous disorder caused by genetic alterations of the TSC1
(9q34) or TSC2 (16p13.3) genes [11], and characterized
by mental retardation, seizures and multiple tumors in
different sites [12]. The role of the TSC genes in the
pathogenesis of sporadic PEComa has still to be eluci-
dated, but recent data suggest that small deletions or
mutations (inactivating or missense) in genes TSC1 or
TSC2 may account for loss of TSC2 expression in those
tumors [5,13]. For a series of 15 PEComas, Kenerson
et al. [14] reported the immunohistochemical evidence
of mTORC1 activity, which suggests loss of TSC1 or
TSC2. The loss of heterozygosity in the TSC1 or TSC2
region has also been reported in seven cases of PEComa
by Pan et al. [15]. These data support inhibition of
mTOR as a rational strategy for treating tumors occur-
ring in TSC or those harboring TSC-related mutations.
Due to its rarity, data on medical treatment for PECo-
mas originate from small case series, most of which
employed the mTOR-inhibitor sirolimus. Wagner et al.
treated three patients with sirolimus, all of whom
showed a radiographic responses [5]. Bissler et al. [7]
described a program of 12 months of treatment followed
by 12 months of observation for angiomyolipoma,
reporting a 53% volume reduction during active therapy,
but also 86% regrowth during the observation period.
This experience underlines the role of continuative
therapy to maintain tumor shrinkage. A case of facialangiofibroma associated with TSC and treated with siro-
limus has been published [8]. One significant response
has been reported with temsirolimus, an alternative
mTOR inhibitor that requires weekly intravenous injec-
tions [9].
Our patient was diagnosed with a large and aggressive
variant of a PEComa, which showed significant shrink-
age after upfront treatment with sirolimus. This allowed
radical removal of the mass without surgical complica-
tions or sequelae. The tolerability of this agent was fairly
good although there were some short treatment breaks
due to gastrointestinal toxicity. The sirolimus plasma
concentration was regularly checked to ensure that any
impairment of liver metabolism due to tumor involve-
ment or interactions with concomitant medications
(ziprasidone and analgesics) did not expose the patient
to excessive drug concentrations.Conclusion
This case is, to our knowledge, the first report of the use
of neoadjuvant sirolimus for malignant PEComa achiev-
ing a significant impact on patient management and
with a possibly curative potential. This confirms the im-
portance of mTOR pathway inhibition in the treatment
of these rare tumors. Tumors deemed inoperable or with
borderline resectability may therefore be evaluated early
for systemic neoadjuvant treatment with sirolimus to ob-
tain tumor shrinkage and facilitate surgical removal. The
option of adjuvant treatment may be considered for se-
lected high-risk patients who can tolerate the mTOR
inhibitor.Consent
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